3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Carboplatin
106
Cisplatin
97
Paclitaxel
78
pembrolizumab
69
Gemcitabine
59
Pemetrexed
49
Cyclophosphamide
46
Docetaxel
45
Dexamethasone
45
durvalumab
44
Capecitabine
44
Radiotherapy
40
Nivolumab
37
Lenalidomide
37
Specimen Handling
36
Doxorubicin
36
Rituximab
34
Oxaliplatin
34
Bevacizumab
33
Magnetic Resonance Spectroscopy
32
Fluorouracil
32
atezolizumab
29
Etoposide
29
Vincristine
26
Radiation
26
Leucovorin
26
Letrozole
24
Bortezomib
24
Fulvestrant
23
Prednisone
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
2019-nCoV Vaccine mRNA-1273
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled